Pfizer Stock News

Timing of income is an important consideration. Monthly dividend stocks provide recurring income and faster compounding of wealth. I highlight two monthly dividend payers that are undervalued while supporting well-covered yields. Both carry strong balance sheets with A- and BBB+ credit ratings and durable business models that support growth for years to come.

Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. I highlight two such names that are undervalued compared to historical norms while paying strong and well-covered dividends. Both carry moat-worthy attributes and provide economically essential products and services that make them recession resilient.

Though indexes have rebounded, the first half of the year has been rocky for investors. The market had to digest a variety of uncertainties, from geopolitical problems to mixed economic data and the U.S. plan to tax imports.

Looking for stocks that pay $100 in annual income? You've come to the right place.

Dividend growth investing is a powerful way to compound wealth and set yourself up for financial independence. However, it also has some real drawbacks. I share 3 aspects of the dark side of dividend growth investing in this article.

Now is a great time to be an income and value investor, particularly in the energy and pharmaceutical spaces. I highlight 2 undervalued names that provide well-covered dividends with a strong growth outlook. The market seems to be overly rotated on near-term headwinds while ignoring the long-term growth drivers, resulting in a dislocation between price and value.

Pfizer's >7% dividend yield is attractive, but faces significant risk due to political, regulatory, and business headwinds impacting revenue and profitability. Major threats include U.S. healthcare policy changes, looming patent expiries, misfiring M&A, heavy debt, and over-reliance on COVID vaccine revenues. Management insists the dividend is safe barring a 'catastrophe,' but current challenge...

The market has become overly pessimistic on Pfizer, focusing on the patent cliff while ignoring the defensive cash flows and offensive catalysts. This has created a classic value opportunity. A fortress 7% dividend yield provides a powerful downside cushion. We analyze the cash flows to show why this payout is secure and offers a compelling return. We model a 'revenue bridge' to demonstrate how...